The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2023 | ETOP clinical trials in EGFR-, KRASG12C- and ALK-mutated NSCLC
Rolf Stahel, MD, ETOP IBCSG Partners Foundation, Berne, Switzerland, discusses the latest clinical research from the European Thoracic Oncology Platform (ETOP), in the EGFR-m positive, KRASG12C+ and ALK+ space, including the STEREO trial which is a multicentre single-arm phase II trial assessing the safety and efficacy of first-line osimertinib and locally ablative radiotherapy in patients with synchronous oligo-metastatic EGFR-mutant non-small cell lung cancer (NSCLC). In addition, Dr Stahel also speaks on the AMAZE-lung trial (NCT05601973) which is evaluating amivantamab, lazertinib plus bevacizumab in patients with EGFR-mutant advanced NSCLC with progression on previous third-generation EGFR-TKI. And in the KRASG12c-mutant NSCLC field, Dr Stahel highlights the ongoing ADEPPT trial (NCT05673187) assessing the clinical efficacy of adagrasib in patients with KRASG12C-mutant NSCLC, including the elderly (≥70 years) or patients with poor performance status. This interview took place at the British Thoracic Oncology Group (BTOG) Annual Conference 2023 in Belfast, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
